drugset / Trial / NCT02618304

Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

NCT02618304

Completed 45 enrolled Yonsei University
NaSingle-groupOpen-labelTreatment

Summary

In this study, investigator aim to evaluate the changes of tear-film lipid layer thickness and ocular aberration after treatment of meibomian gland dysfunction. In case of stage 3 or 4 meibomian gland dysfunction, participants will be treated using conventional treatment modalities. Before treatment and after 1 and 2 months of treatment, a variety of ophthalmic examination, tear-film lipid layer thickness, and ocular aberration are going to measured and compared.

Timeline

Start
2015-04-20
Primary completion
2016-02-19
Completion
2016-02-19

Drugs

EvaluationDrugModalityDoseRoute
Background Diquafosol tetrasodium Oligonucleotide (other) 3 % Topical

Indications